These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1291 related items for PubMed ID: 27242368

  • 1. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
    Sanders JS, de Joode AA, DeSevaux RG, Broekroelofs J, Voskuyl AE, van Paassen P, Kallenberg CG, Tervaert JW, Stegeman CA.
    Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
    [Abstract] [Full Text] [Related]

  • 2. Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data.
    de Joode AAE, Sanders JSF, Puéchal X, Guillevin LP, Hiemstra TF, Flossmann O, Rasmussen N, Westman K, Jayne DR, Stegeman CA.
    Rheumatology (Oxford); 2017 Nov 01; 56(11):1894-1901. PubMed ID: 28977502
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
    Jayne D, Blockmans D, Luqmani R, Moiseev S, Ji B, Green Y, Hall L, Roth D, Henderson RB, Merkel PA, BREVAS Study Collaborators.
    Arthritis Rheumatol; 2019 Jun 01; 71(6):952-963. PubMed ID: 30666823
    [Abstract] [Full Text] [Related]

  • 4. Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse.
    Morgan MD, Szeto M, Walsh M, Jayne D, Westman K, Rasmussen N, Hiemstra TF, Flossmann O, Berden A, Höglund P, Harper L, European Vasculitis Society.
    Arthritis Res Ther; 2017 Jun 07; 19(1):129. PubMed ID: 28592297
    [Abstract] [Full Text] [Related]

  • 5. The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.
    Berti A, Warner R, Johnson K, Cornec D, Schroeder DR, Kabat BF, Langford CA, Kallenberg CGM, Seo P, Spiera RF, St Clair EW, Fervenza FC, Stone JH, Monach PA, Specks U, Merkel PA, RAVE-ITN Research Group.
    J Autoimmun; 2019 Dec 07; 105():102302. PubMed ID: 31320177
    [Abstract] [Full Text] [Related]

  • 6. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
    Unizony S, Villarreal M, Miloslavsky EM, Lu N, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CM, St Clair EW, Ikle D, Tchao NK, Ding L, Brunetta P, Choi HK, Monach PA, Fervenza F, Stone JH, Specks U, RAVE-ITN Research Group.
    Ann Rheum Dis; 2016 Jun 07; 75(6):1166-9. PubMed ID: 26621483
    [Abstract] [Full Text] [Related]

  • 7. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis.
    Slot MC, Tervaert JW, Boomsma MM, Stegeman CA.
    Arthritis Rheum; 2004 Apr 15; 51(2):269-73. PubMed ID: 15077271
    [Abstract] [Full Text] [Related]

  • 8. Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.
    Fussner LA, Hummel AM, Schroeder DR, Silva F, Cartin-Ceba R, Snyder MR, Hoffman GS, Kallenberg CG, Langford CA, Merkel PA, Monach PA, Seo P, Spiera RF, William St Clair E, Tchao NK, Stone JH, Specks U, Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group.
    Arthritis Rheumatol; 2016 Jul 15; 68(7):1700-10. PubMed ID: 26882078
    [Abstract] [Full Text] [Related]

  • 9. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment.
    Sanders JS, Huitma MG, Kallenberg CG, Stegeman CA.
    Rheumatology (Oxford); 2006 Jun 15; 45(6):724-9. PubMed ID: 16399845
    [Abstract] [Full Text] [Related]

  • 10. Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Wallace ZS, Fu X, Liao K, Kallenberg CGM, Langford CA, Merkel PA, Monach P, Seo P, Specks U, Spiera R, St Clair EW, Zhang Y, Choi H, Stone JH.
    Arthritis Rheumatol; 2019 Nov 15; 71(11):1879-1887. PubMed ID: 31162829
    [Abstract] [Full Text] [Related]

  • 11. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.
    Karras A, Pagnoux C, Haubitz M, Groot K, Puechal X, Tervaert JWC, Segelmark M, Guillevin L, Jayne D, European Vasculitis Society.
    Ann Rheum Dis; 2017 Oct 15; 76(10):1662-1668. PubMed ID: 28546260
    [Abstract] [Full Text] [Related]

  • 12. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
    Terrier B, Pagnoux C, Perrodeau É, Karras A, Khouatra C, Aumaître O, Cohen P, Decaux O, Desmurs-Clavel H, Maurier F, Gobert P, Quémeneur T, Blanchard-Delaunay C, Bonnotte B, Carron PL, Daugas E, Ducret M, Godmer P, Hamidou M, Lidove O, Limal N, Puéchal X, Mouthon L, Ravaud P, Guillevin L, French Vasculitis Study Group.
    Ann Rheum Dis; 2018 Aug 15; 77(8):1150-1156. PubMed ID: 29724729
    [Abstract] [Full Text] [Related]

  • 13. ANCA-associated vasculitis: diagnostic and therapeutic strategy.
    Ozaki S.
    Allergol Int; 2007 Jun 15; 56(2):87-96. PubMed ID: 17460438
    [Abstract] [Full Text] [Related]

  • 14. Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Pepper RJ, Draibe JB, Caplin B, Fervenza FC, Hoffman GS, Kallenberg CG, Langford CA, Monach PA, Seo P, Spiera R, William St Clair E, Tchao NK, Stone JH, Specks U, Merkel PA, Salama AD, RAVE-Immune Tolerance Network Research Group.
    Arthritis Rheumatol; 2017 Jan 15; 69(1):185-193. PubMed ID: 27428710
    [Abstract] [Full Text] [Related]

  • 15. Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial.
    Gopaluni S, Smith RM, Lewin M, McAlear CA, Mynard K, Jones RB, Specks U, Merkel PA, Jayne DR, RITAZAREM Investigators.
    Trials; 2017 Mar 07; 18(1):112. PubMed ID: 28270229
    [Abstract] [Full Text] [Related]

  • 16. Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial.
    Maritati F, Alberici F, Oliva E, Urban ML, Palmisano A, Santarsia F, Andrulli S, Pavone L, Pesci A, Grasselli C, Santi R, Tumiati B, Manenti L, Buzio C, Vaglio A.
    PLoS One; 2017 Mar 07; 12(10):e0185880. PubMed ID: 29016646
    [Abstract] [Full Text] [Related]

  • 17. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial.
    Jones RB, Hiemstra TF, Ballarin J, Blockmans DE, Brogan P, Bruchfeld A, Cid MC, Dahlsveen K, de Zoysa J, Espigol-Frigolé G, Lanyon P, Peh CA, Tesar V, Vaglio A, Walsh M, Walsh D, Walters G, Harper L, Jayne D, European Vasculitis Study Group (EUVAS).
    Ann Rheum Dis; 2019 Mar 07; 78(3):399-405. PubMed ID: 30612116
    [Abstract] [Full Text] [Related]

  • 18. Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission in Nonlife-Threatening Relapses of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Randomized, Controlled Trial.
    Tuin J, Stassen PM, Bogdan DI, Broekroelofs J, van Paassen P, Cohen Tervaert JW, Sanders JS, Stegeman CA.
    Clin J Am Soc Nephrol; 2019 Jul 05; 14(7):1021-1028. PubMed ID: 31253599
    [Abstract] [Full Text] [Related]

  • 19. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.
    Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Ding L, Iklé D, Villareal M, Lim N, Brunetta P, Fervenza FC, Monach PA, Stone JH, Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group.
    Arthritis Rheumatol; 2015 Jun 05; 67(6):1629-36. PubMed ID: 25776953
    [Abstract] [Full Text] [Related]

  • 20. Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis.
    Thompson GE, Fussner LA, Hummel AM, Schroeder DR, Silva F, Snyder MR, Langford CA, Merkel PA, Monach PA, Seo P, Spiera RF, St Clair EW, Stone JH, Specks U.
    Front Immunol; 2020 Jun 05; 11():2053. PubMed ID: 33013868
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.